European Leukemia Trial Registry
Trial: AZALE

More Details
Scientific Title A phase I study of a combination of 5-azacitidine followed by lenalidomide in high-risk MDS RAEB or relapsed/refractory AML patients with cytogenetic abnormalities including –5 or del(5q)
Short Title AZALE
Trialgroup Deutsche MDS
Type of Trial multicentric, single-group, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 18 years
Status Closed
Start of Recruitment 30.10.2008
Leader Platzbecker, Prof. Dr. med., Uwe
Contactperson

principal investigator
Platzbecker, Prof. Dr. med., Uwe
Tel: +49 (0)351 4582583
Fax: +49 (0)351 458-5362
Email: Uwe.Platzbecker@uniklinikum-dresden.de

Centre of Trial Universitätsklinikum Carl Gustav Carus, Dresden
Shortprotocol Shortprotocol
Diagnostics

DNA-Mythylation
Genexpressionslabor der Med. Klinik III, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin

gene expression
Hämatologisches Labor, Universitätsklinikum Dresden

created 30.10.2008 5 Roswitha Kotthoff
changed 05.11.2014 Hanna Ebert
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org